J2 Capital Management Inc Takes $521,000 Position in Medpace Holdings, Inc. $MEDP

J2 Capital Management Inc purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,086 shares of the company’s stock, valued at approximately $521,000.

Other hedge funds have also recently made changes to their positions in the company. Capital Fund Management S.A. raised its stake in shares of Medpace by 129.5% during the third quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock valued at $16,665,000 after acquiring an additional 18,287 shares in the last quarter. Dorsey Wright & Associates bought a new position in Medpace in the third quarter worth approximately $5,082,000. Victory Capital Management Inc. grew its stake in Medpace by 32.9% in the third quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock worth $15,702,000 after purchasing an additional 7,565 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Medpace by 9.9% during the 3rd quarter. Fisher Asset Management LLC now owns 137,746 shares of the company’s stock worth $70,824,000 after purchasing an additional 12,399 shares during the period. Finally, Intech Investment Management LLC increased its holdings in Medpace by 31.9% during the 3rd quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock worth $9,458,000 after purchasing an additional 4,448 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 1.4%

Shares of NASDAQ:MEDP opened at $519.96 on Friday. The firm has a 50 day moving average of $451.02 and a 200 day moving average of $496.81. The company has a market capitalization of $14.85 billion, a price-to-earnings ratio of 32.68, a price-to-earnings-growth ratio of 2.60 and a beta of 1.18. Medpace Holdings, Inc. has a 52 week low of $305.69 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the firm earned $3.67 EPS. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Robert W. Baird lowered their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada lowered their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Barclays dropped their target price on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $467.08.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.